antibodies

Strategies including parasite-based vaccines, mosquito-transmission blockers, and antibody drugs are promising new ways to target the disease.  

Sepsis antibody breakthroughs, a billion-dollar KRAS deal, and FDA’s push to rebuild domestic drug manufacturing led the drug discovery news this week.

With new insight into IgE biology, a new, two-pronged strategy for eliminating the pathogenic immune cells that lead to allergies emerges.

A new method to tag and track different antibody drugs in the same mouse reduces the number of animals needed in preclinical studies.

Scientists probed how tick proteins influenced host immunity, paving the way for mRNA vaccines to block Lyme and other tick-borne diseases.

Omalizumab could be a better treatment for children with food allergies compared to oral immunotherapy, mainly due to fewer side effects.

A new vaccination schedule pumps up the immune response to human immunodeficiency virus, overcoming a barrier that has frustrated vaccine designers.

There is no vaccine against this parasitic worm infection, but rhesus macaques’ unique immune system has brought the prospect of a vaccine closer than ever.

Scientists discover an ultra-rare monoclonal antibody directly from patients with autoimmune diseases.

A new model predicts how well maternal vaccines protect babies from Group B Streptococcus, propelling much needed shots through late-stage clinical trials.